871580-95-9

Basic information

• Product Name: (1R,2R)-2-hydroxy-1-methylpropyl (2S)-2-[(tert-butoxy)carbonylamino]-3-[3,4-bis(phenylmethoxy)phenyl]propanoate
• Synonyms: (1R,2R)-2-hydroxy-1-methylpropyl (2S)-2-[(tert-butoxy)carbonylamino]-3-[3,4-bis(phenylmethoxy)phenyl]propanoate
• CAS NO: 871580-95-9
• Molecular Weight: 549.664
• Mol File: 871580-95-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (1R,2R)-2-hydroxy-1-methylpropyl (2S)-2-[(tert-butoxy)carbonylamino]-3-[3,4-bis(phenylmethoxy)phenyl]propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,2R)-2-hydroxy-1-methylpropyl (2S)-2-[(tert-butoxy)carbonylamino]-3-[3,4-bis(phenylmethoxy)phenyl]propanoate(871580-95-9)
• EPA Substance Registry System: (1R,2R)-2-hydroxy-1-methylpropyl (2S)-2-[(tert-butoxy)carbonylamino]-3-[3,4-bis(phenylmethoxy)phenyl]propanoate(871580-95-9)

Safety Data

• Hazardous Substances Data: 871580-95-9(Hazardous Substances Data)

Upstream product

• 24347-58-8 (R,R)-2,3-butandiol 
• 59727-98-9 3-[3,4-di(benzyloxy)phenyl]-2-{[(tert-butoxy)carbonyl]amino}propanoic acid 

Downstream Products

• 1033891-31-4 (1R,2R)-2-acetyloxy-1-methylpropyl (2S)-2-[(tert-butoxy)carbonylamino]-3-[3,4-bis(phenylmethoxy)phenyl]propanoate 
• 871580-96-0 (1R,2R)-1-methyl-2-phenylcarbonyloxypropyl (2S)-2-[(tert-butoxy)carbonylamino]-3-[3,4-bis(phenylmethoxy)phenyl]propanoate 
• 871580-97-1 (1R,2R)-1-methyl-2-phenylcarbonyloxypropyl (2S)-3-(3,4-dihydroxyphenyl)-2-[(tert-butoxy)carbonylamino]-propanoate 
• 871580-42-6 (1R,2R)-1-methyl-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)-propanoate hydrochloride 

Relevant articles and documents

LEVODOPA DIMETHYL-SUBSTITUTED DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE

Levodopa dimethyl-substituted diester prodrugs, pharmaceutical, compositions comprising levodopa dimethyl-substituted diester prodrugs, and methods of using such prodrugs and pharmaceutical compositions for treating diseases such as Parkinson's disease are provided. Formula (I)

LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF

Prodrugs of levodopa, methods of making prodrugs of levodopa, methods of using prodrugs of levodopa, and compositions of prodrugs of levodopa are disclosed. Wherein Q is selected from X-CO-, and -CO-X-; X is selected from-O-, and -NR6-; n is an